BSN
Fintech Finessen (B2C-Showcase hier)

Inbox: Ex-Valneva-CFO Kandera wird CFO bei ...


19.04.2017

Zugemailt von / gefunden bei: Hookipa (BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)

Hookipa Biotech AG

Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech

Vienna, Austria, 19 April 2017 - Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces that Reinhard Kandera has joined the Company as Chief Financial Officer (CFO). Effective June 1st, 2017, he will also become a member of Hookipa’s management board.

Reinhard Kandera has more than 20 years of professional experience in the finance and healthcare industries including 15 years as senior executive within biotech companies. Immediately prior to joining Hookipa, he was a Member of the Management Board and CFO of Valneva SE, a commercial stage biotech vaccine company, listed on the Euronext Paris and the Vienna Stock Exchange.

Prior to his role at Valneva, he was CFO and member of the Management Board of Intercell AG, another publicly listed European biotech company, which was merged with Vivalis SA to become Valneva in 2013. Before becoming Intercell’s CFO, Reinhard Kandera held various other positions at Intercell, including Global Head of Finance, and Investor Relations and CFO of Intercell USA (the formerly NASDAQ-listed Iomai Corporation). Reinhard played a pivotal role in the IPO of Intercell in 2005, multiple public and private financings exceeding hundreds of millions of euros/dollars, the acquisition and integration of businesses in Scotland, the USA, Switzerland and Sweden as well as the European cross-border merger that created Valneva. Reinhard Kandera started his career in the finance industry at Deutsche Bank AG where he held positions with increasing responsibility. He holds doctorate degrees in Business Administration and in Law from the Vienna University of Economics and Business, and the Vienna University’s Faculty of Law, respectively.

Commenting on the appointment, Hookipa´s CEO, Mr. Jörn Aldag said: “I am very pleased to welcome Reinhard to our team, at an important juncture for Hookipa, particularly in light of our expanded strategic ambitions and the extension of our portfolio to include immuno-oncology. The breadth of Reinhard´s financial and transactional experience will make an invaluable addition to our development as well as in considering and executing on financing options.”

Dr. Kandera said, “With its novel Vaxwave® and TheraT® platforms, Hookipa has a strong technology foundation and I am excited to have the opportunity to contribute to the Company’s growth and to help the Company to deliver on its ambition of bringing next-generation cancer immune therapeutics and vaccines to patients.”

Reinhard Kandera (CFO Valneva) © Martina Draper/photaq


(BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)

Indizes
ATX 3162 -1.14 % 3171 0.28% 09:25:41
DAX 12240 -1.66 % 12257 0.13% 09:25:41
Dow 21580 -0.15 % 21564 -0.07% 09:27:25
Nikkei 20100 -0.22 % 19980 -0.60% 23:50:15
Gold 1250 0.88 % 1255 0.38% 22:59:57



Fachheft aktuell

Geschäftsberichte

Inbox: Ex-Valneva-CFO Kandera wird CFO bei ...


19.04.2017

19.04.2017

Zugemailt von / gefunden bei: Hookipa (BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)

Hookipa Biotech AG

Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech

Vienna, Austria, 19 April 2017 - Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces that Reinhard Kandera has joined the Company as Chief Financial Officer (CFO). Effective June 1st, 2017, he will also become a member of Hookipa’s management board.

Reinhard Kandera has more than 20 years of professional experience in the finance and healthcare industries including 15 years as senior executive within biotech companies. Immediately prior to joining Hookipa, he was a Member of the Management Board and CFO of Valneva SE, a commercial stage biotech vaccine company, listed on the Euronext Paris and the Vienna Stock Exchange.

Prior to his role at Valneva, he was CFO and member of the Management Board of Intercell AG, another publicly listed European biotech company, which was merged with Vivalis SA to become Valneva in 2013. Before becoming Intercell’s CFO, Reinhard Kandera held various other positions at Intercell, including Global Head of Finance, and Investor Relations and CFO of Intercell USA (the formerly NASDAQ-listed Iomai Corporation). Reinhard played a pivotal role in the IPO of Intercell in 2005, multiple public and private financings exceeding hundreds of millions of euros/dollars, the acquisition and integration of businesses in Scotland, the USA, Switzerland and Sweden as well as the European cross-border merger that created Valneva. Reinhard Kandera started his career in the finance industry at Deutsche Bank AG where he held positions with increasing responsibility. He holds doctorate degrees in Business Administration and in Law from the Vienna University of Economics and Business, and the Vienna University’s Faculty of Law, respectively.

Commenting on the appointment, Hookipa´s CEO, Mr. Jörn Aldag said: “I am very pleased to welcome Reinhard to our team, at an important juncture for Hookipa, particularly in light of our expanded strategic ambitions and the extension of our portfolio to include immuno-oncology. The breadth of Reinhard´s financial and transactional experience will make an invaluable addition to our development as well as in considering and executing on financing options.”

Dr. Kandera said, “With its novel Vaxwave® and TheraT® platforms, Hookipa has a strong technology foundation and I am excited to have the opportunity to contribute to the Company’s growth and to help the Company to deliver on its ambition of bringing next-generation cancer immune therapeutics and vaccines to patients.”

Reinhard Kandera (CFO Valneva) © Martina Draper/photaq



Was noch interessant sein dürfte:


Inbox: Weiterer IPO-Versuch von Varta wird geprüft

Inbox: Referendum Türkei: Einschätzung Deutsche Asset Management, was nun am Finanzmarkt passieren wird

Inbox: Wiener Börse zum Weltfondstag: Wie Anleger in österreichischen Aktien den Standort stärken

Fabasoft und Polytec vs. voestalpine und FACC – kommentierter KW 15 Peer Group Watch OÖ10 Members

KTM Industries und Hella Hueck & Co vs. FACC und Schaeffler – kommentierter KW 15 Peer Group Watch Börseneulinge

Nebenwerte-Blick: Porr und KTM am Gründonnerstag sehr grün

Inbox: Post zahlt 2 Euro je Aktie Dividende

Audio: ATX vs. DAX, Einschätzung #invest17 und Wiener Börse (Audio 5:19 #boersenradio)

Audio: Marianne Kögel (RCB) stellt via Börsenradio ein Bonuszertifikat vor (Audio 7:48 #boersenradio)



Reinhard Kandera (CFO Valneva), (© Martina Draper/photaq)


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten



Partner
Indizes
ATX 3162 -1.14 % 3171 0.28% 09:25:41
DAX 12240 -1.66 % 12257 0.13% 09:25:41
Dow 21580 -0.15 % 21564 -0.07% 09:27:25
Nikkei 20100 -0.22 % 19980 -0.60% 23:50:15
Gold 1250 0.88 % 1255 0.38% 22:59:57



Fachheft aktuell

Geschäftsberichte